Stockscreener 앱 받기
3.54
4.73%
0.16
시간 외 거래:
3.59
0.05
+1.41%
Ataibeckley Inc 주식(ATAI)의 최신 뉴스
Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003? - Insider Monkey
Ataibeckley Insider Sold Shares Worth $355,000, According to a Recent SEC Filing - marketscreener.com
AtaiBeckley chief medical officer Craig Kevin James sells $355,000 in stock - Investing.com
Small cap wrap: Fox Tungsten, AtaiBeckley, Ocean Power Technologies, Abacus Global Management… - Proactive Investors
AtaiBeckley added to major US indices, increasing reach among passive investors - Yahoo Finance
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst - Bitget
AtaiBeckley added to S&P Total Market, CRSP benchmark indices - Investing.com
AtaiBeckley Inc. Added to S&P Total Market Index and CRSP U.S. Benchmark Indices, Enhancing Market Presence and Driving Index Fund Position-Building - Quiver Quantitative
AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg - MSN
AtaiBeckley Inc.(NasdaqGM: ATAI) added to S&P TMI Index - marketscreener.com
[144] Atai Beckley N.V. SEC Filing - Stock Titan
AtaiBeckley sees promising mid-stage results for psychedelic antidepressant - MSN
AtaiBeckley Advances BPL-003 Program As Beckley Psytech Deal Closes - simplywall.st
AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish (NASDAQ:ATAI) - Seeking Alpha
Assessing AtaiBeckley (ATAI) Valuation As Strong Long Term Returns Contrast With Heavy Losses - Yahoo Finance
AtaiBeckley: Advancing BPL-003 Into Pivotal Phase 3 With Strategic Optionality and Strong Cash Runway Supporting a Buy Rating - TipRanks
H.C. Wainwright reiterates atai Life Sciences stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates atai Life Sciences stock rating at buy - Investing.com
AtaiBeckley publishes Phase 2a data for depression treatment By Investing.com - Investing.com South Africa
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
Weighing AtaiBeckley (ATAI) Valuation After Recent Share Price Volatility - simplywall.st
Small cap wrap: AtaiBeckley, New Era Energy & Digital, Standard Uranium, Namibia Critical Metals… - Proactive Investors
H.C. Wainwright Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003 - Proactive financial news
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation - Bitget
AtaiBeckley publishes Phase 2a data for depression treatment - Investing.com
AtaiBeckley Inc. Publishes Positive Phase 2a Study Results of BPL-003 for Treatment-Resistant Depression in Journal of Psychopharmacology - Quiver Quantitative
Single-dose nasal spray eases treatment-resistant depression in 12-patient trial - Stock Titan
Atai Beckley NV (ATAI) is a buy on mental therapeutics opportunities - MSN
symbol__ Stock Quote Price and Forecast - CNN
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 By Investing.com - Investing.com Nigeria
Why AtaiBeckley (ATAI) Is Up 10.0% After FDA Backs BPL-003 Phase 3 Depression Trials - simplywall.st
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal - Psychedelic Alpha
Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published - Psychedelic Alpha
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise - TradingView
ATAI: Short-duration psychedelic therapies show strong efficacy and commercial promise in mental health - TradingView
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting, AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - marketscreener.com
H.C. Wainwright Maintains Buy on ATAI Atai Beckley N.V Mar 2026 - Meyka
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
AtaiBeckley plans Phase 3 trials for depression treatment in Q2 - Investing.com South Africa
4 Analysts Have This To Say About AtaiBeckley - Sahm
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day - Yahoo Finance
AtaiBeckley Social Anxiety Treatment A Game-Changer: AnalystsAtaiBeckley (NASDAQ:ATAI) - Benzinga
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - Investing News Network
1.82%
자본화:
|
볼륨(24시간):